Legal & General Group
ELEV

Legal & General Group’s Elevation Oncology ELEV Stock Holding History

Legal & General Group’s Portfolio ELEV Stock Details ELEV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-5,287
Closed -$1.37K – 3454
2025
Q1 		$1.37K Hold
5,287
– – ﹤0.01% 3367
2024
Q4 		$2.97K Hold
5,287
– – ﹤0.01% 3370
2024
Q3 		$3.17K Hold
5,287
– – ﹤0.01% 3385
2024
Q2 		$14.3K Buy
+5,287
New +$19.9K ﹤0.01% 3164

Other funds holding ELEV

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
RC
Rangeley Capital New Canaan, Connecticut $103M AUM 77.32% 1-Year Est. Return
ECM
ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return

Legal & General Group's ELEV Position: Q2 2025 in Review

Legal & General Group sold out of Elevation Oncology (ELEV) in Q2 2025, closing a stake of 5,287 shares — an estimated $1.37K sold.

Legal & General Group first reported a position in ELEV in Q2 2024 and held it in 4 quarters. The position peaked at $14.3K in Q2 2024. 65 funds tracked by Wall St. Rank hold ELEV as of Q2 2025.

  • Legal & General Group reported no remaining Elevation Oncology position as of Q2 2025 after selling out during the quarter.
  • Legal & General Group sold 5,287 Elevation Oncology shares in Q2 2025, an estimated $1.37K.
  • Legal & General Group first reported a position in Elevation Oncology in Q2 2024 and held it in 4 quarters.
  • Legal & General Group's Elevation Oncology position peaked at $14.3K in Q2 2024.
  • 65 funds tracked by Wall St. Rank held Elevation Oncology as of Q2 2025.

Based on Legal & General Group's 13F filing for Q2 2025, filed 12 Aug 2025.